Literature DB >> 26652134

Expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherin in localized prostate cancer.

Alexandros Drivalos1, Michael Chrisofos2, Eleni Efstathiou3, Amalia Kapranou4, Gerasimos Kollaitis5, Georgios Koutlis4, Nick Antoniou5, Dimitrios Karanastasis5, Meletios A Dimopoulos3, Aristotelis Bamias3.   

Abstract

OBJECTIVE: To explore the correlation between the expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherin in prostate cancer (PCa) and its clinicopathological data including tumor grade and clinical stage.
METHODS: The expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherin was examined in 157 cases of PCa and adjacent normal prostatic tissue by immunohistochemical assay, and the correlation with clinicopathological features was analyzed.
RESULTS: Expressions of α5-integrin, α7-integrin, and Ε-cadherin in PCa were lower than those in normal prostatic tissues (P<0.05). N-cadherin expression was higher in cancer prostatic tissue than in normal prostatic tissues (P<0.05). The reduced expression of α5-integrin, α7-integrin, and Ε-cadherin was related to Gleason score, pathological stage, lymph node metastasis, and prostate-specific antigen level, but it was not associated with positive surgical margins and patient age. The increased expression of N-cadherin was related to Gleason score, pathological stage, lymph node metastasis, and prostate-specific antigen level, but not to age and positive surgical margins. The expression of E-cadherin was highly negatively correlated with that of N-cadherin and also positively correlated with that of α5-integrin and α7-integrin.
CONCLUSION: The reduced expression of α5-integrin, α7-integrin, and Ε-cadherin and abnormal expression of N-cadherin play an important role in the occurrence and development of PCa. The results indicate that these have potential values in the diagnosis and are predictable indices in the proliferation of PCa.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cadherins; Cell adhesion molecules; Integrins; Prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26652134     DOI: 10.1016/j.urolonc.2015.10.016

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  14 in total

1.  Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.

Authors:  Catarina Ferreira; João Lobo; Luís Antunes; Paula Lopes; Carmen Jerónimo; Rui Henrique
Journal:  Virchows Arch       Date:  2018-07-13       Impact factor: 4.064

2.  Prostate cancer sheds the αvβ3 integrin in vivo through exosomes.

Authors:  Shiv Ram Krishn; Amrita Singh; Nicholas Bowler; Alexander N Duffy; Andrea Friedman; Carmine Fedele; Senem Kurtoglu; Sushil K Tripathi; Kerith Wang; Adam Hawkins; Aejaz Sayeed; Chirayu P Goswami; Madhukar L Thakur; Renato V Iozzo; Stephen C Peiper; William K Kelly; Lucia R Languino
Journal:  Matrix Biol       Date:  2018-08-08       Impact factor: 11.583

3.  Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?

Authors:  Ece Konac; Ilker Kiliccioglu; Emrullah Sogutdelen; Asiye U Dikmen; Gulsah Albayrak; Cenk Y Bilen
Journal:  Exp Biol Med (Maywood)       Date:  2017-08-24

4.  Microscopic pulmonary tumor embolism from adenocarcinoma of the prostate.

Authors:  Tatsuya Hattori; Yosuke Ikegami; Nayuka Matsuyama; Takashi Hamakawa; Tetsuji Maruyama; Aya Naiki-Ito; Takahiro Yasui
Journal:  IJU Case Rep       Date:  2020-06-18

Review 5.  Upregulated N-cadherin expression is associated with poor prognosis in epithelial-derived solid tumours: A meta-analysis.

Authors:  Yong Luo; Ting Yu; Qiongwen Zhang; Qingyu Fu; Yuzhu Hu; Mengmeng Xiang; Haoning Peng; Tianying Zheng; Li Lu; Huashan Shi
Journal:  Eur J Clin Invest       Date:  2018-02-25       Impact factor: 4.686

6.  Epithelial-To-Mesenchymal Transition Markers and CD44 Isoforms Are Differently Expressed in 2D and 3D Cell Cultures of Prostate Cancer Cells.

Authors:  Fabrizio Fontana; Michela Raimondi; Monica Marzagalli; Michele Sommariva; Patrizia Limonta; Nicoletta Gagliano
Journal:  Cells       Date:  2019-02-11       Impact factor: 6.600

Review 7.  Role of Cadherins in Cancer-A Review.

Authors:  Ilona Kaszak; Olga Witkowska-Piłaszewicz; Zuzanna Niewiadomska; Bożena Dworecka-Kaszak; Felix Ngosa Toka; Piotr Jurka
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

8.  HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression.

Authors:  Jasmina Makarević; Jochen Rutz; Eva Juengel; Sebastian Maxeiner; Jens Mani; Stefan Vallo; Igor Tsaur; Frederik Roos; Felix K-H Chun; Roman A Blaheta
Journal:  Cells       Date:  2018-09-01       Impact factor: 6.600

Review 9.  N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer.

Authors:  Krzysztof Marek Mrozik; Orest William Blaschuk; Chee Man Cheong; Andrew Christopher William Zannettino; Kate Vandyke
Journal:  BMC Cancer       Date:  2018-10-01       Impact factor: 4.430

10.  Small extracellular vesicles modulated by αVβ3 integrin induce neuroendocrine differentiation in recipient cancer cells.

Authors:  Fabio Quaglia; Shiv Ram Krishn; George G Daaboul; Srawasti Sarker; Raffaella Pippa; Josep Domingo-Domenech; Gaurav Kumar; Paolo Fortina; Peter McCue; William K Kelly; Himisha Beltran; Qin Liu; Lucia R Languino
Journal:  J Extracell Vesicles       Date:  2020-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.